It has developed a test delivering results in under three hours from a positive blood bottle or 3 to 4 hours from a raw urine sample, saving lives and reducing the spread of antimicrobial resistance.
iFAST Diagnostics has raised €5.8M across 1 funding round from 7 investors, most recently a round in May 2026. Based in London, UK; active in Healthtech. Data as of 7 Aug 2026.
Timing: too soon vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2026-05-27 | Other |
| €5.8M |
| Qantx,existing subscribers,Innovate UK grant,members of Cambridge Capital Group,Meridian Health Ventures (MHV),OKG Capital+1 more |
| View deal → |
